Use of methoxy polyethylene glycol-epoetin beta in stage 3, 4 or 5 non-dialysis chronic kidney disease;Utilización de eritropoyetina beta pegilada en enfermedad renal crónica en estadio 3, 4 o 5 no-D

Nefrologia

Volumn 32, Issue 2, 2012, Pages 221-227

  Padullés Zamora, Núria ^a   Comas Sugrañes, Dolors ^a   del Mar Pineda Yuste, M ^a   Jódar Masanés, Ramon ^a   Martínez Castelao, Alberto ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Anemia; Chronic kidney disease; Cost; Epoetinalpha; Haemoglobin; Polyethylene glycol epoetin beta

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; MACROGOL DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 84864408204     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2011.Dec.11159     Document Type: Article

References (11)

1. Cabrera L, Ruiz B, Sancho A. Eritropoyetina: revisión de sus indicaciones. IT del sistema nacional de salud 2009;33(1):3-9.
2. KDOQI clinical practice guideline and clinical practice recommendations for anaemia in chronic kidney disease, 2007 update of haemoglobin target. AM J Kidney Dis 2007;50(3):471-530
3. KDOQI; National Kidney Foundation. II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47(5 Suppl 3):s16-85.
4. Drueke TB, Locatelli F, Clyne N, Eckardit KU, Macdougall IC, Tsaris D, et al; CREATE Investigators. Normalization oh haemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-84.
5. Singh AK, Szeczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al D; CHOIR investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355(20):2085-98.
6. Ortega LM, Contreras G. El impacto clínico de los efectos fisiológicos de la eritropoyetina y de los agentes estimulantes de la eritropoyetina en la incidencia de malignidad, trombosis e hipertensión: más allá de la anemia. Nefrologia 2009;29(4):288-94.
7. FDA. Information for Healthcare Professionals. Erythropoiesis Stimulating Agents (ESA). Available at: http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm077123.htm.8.
8. European Medicines Agency. Post-authorisation Evaluation of Medicines for Human Use. Public Statement. European Medicines Agency starts review of the safety of epoetins, London, 27 April 2007 Doc. Ref. EMEA/188068/2007.EMEA/188068/2007.
9. Locatelli F, Nissenson AR, Barrett BJ, Walker RG, Wheeler DC, Eckardt KU, et al. Clinical practice guideline for anaemia in chronic kidney disease: problems and solutions. A position statement from kidney disease: Improving Global outcomes (KDIGO). Kidney Int 2008;74(10):1237-40.
10. Martín A, Aljama P, Arias M, Górriz JL, Martínez Castelao A, Portolés J. ¿Es necesario cambiar los niveles actuales de hemoglobina diana en pacientes con enfermedad renal crónica? A propósito del «boxed warning» de la FDA y del «public statement» de la EMEA. Nefrologia 2007;27(4):399-404.
11. Martínez-Castelao A, on behalf of the CORDATUS Study Investigators. CERA once every 4 weeks corrects anemia in chronic renal disease with low incidence of Hb values outside the target range. XL ERA/EDTA Congress. Munich, 25-28 June 2010.